DTIL - precisionbiosciences.com Market Capitalization-to-Revenue Ratio

Corporate company logo of Precision BioSciences (DTIL)

The resilience of the Precision BioSciences (DTIL) model is based on the automation of gene editing via AI systems. The ratio of trading value to revenue visualizes this trend, where 4.90 shows the current value of the metric. High precision in DNA modifications reduces mutation risks, while stringent FDA requirements and patent protection create a powerful barrier for new entrants in the biomedicine sector.

Precision BioSciences - DTIL P/S Multiple (period 07/04/2022 - 11/13/2026)

Metric breakdowns and analytics for Precision BioSciences (DTIL)

- stock price and consensus target price:
Share Price Precision BioSciences Inc.|DTIL - Consensus Target
- market capitalization statistics:
Market Value Precision BioSciences|DTIL - Enterprise Value
- book capitalization indicators:
Net Assets per Single Share Precision BioSciences|DTIL - Book Capitalization|Market Capitalization to Book Value precisionbiosciences.com|DTIL - Aggregate Company Assets
- debt obligations and liquidity statistics:
Debt to Capital Precision BioSciences|DTIL - Long-Term Debt to Equity|Short-Term Debt to Capital Coefficient precisionbiosciences.com|DTIL - Company Aggregate Debts|Debt to Book Value Precision BioSciences|DTIL - Company Long-Term Debts|Short-Term Debt Volume Precision BioSciences|Immediate Liquidity precisionbiosciences.com
- financial results and valuation multiples details:
DTIL - Company Net Income|Net Profit Forecast Precision BioSciences|DTIL - P/E Multiple|Projected Price to Earnings Precision BioSciences Inc.|DTIL - PEG Multiple|Company Value to EBITDA Precision BioSciences|DTIL - Profit before payment of interest, taxes and amortization|Net earnings per share for the last four quarters Precision BioSciences|DTIL - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last 12 months precisionbiosciences.com|DTIL - Net earnings per share growth this year|Projected earnings per share increase next year Precision BioSciences
- issuer revenue and sales details:
DTIL - Revenue and Sales Volume|Company Future Sales precisionbiosciences.com|DTIL - Price-to-Revenue Ratio|Price-to-Projected Revenue Ratio Precision BioSciences
General company analysis:DTIL (Precision BioSciences Inc.)
Mass-produced product of Precision BioSciences

For Precision BioSciences (DTIL), whose biotechnological developments are isolated from macroeconomic fluctuations, the P/S ratio serves as a key tool for assessing market value. This metric is calculated as the ratio of market capitalization to annual revenue, determining the value of each dollar of sales. By analyzing the price/sales multiple, an investor can identify phases of asset overheating or undervaluation. Stable demand for drugs makes this indicator a reliable filter for long-term planning.

Competing companies

Tempus AI - Market Cap to Revenue Ratio|Qiagen - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio IONS|Repligen Corp. - P/S Multiple|RNA: Price-to-Revenue Ratio|CRSP: P/S Multiple|WGS - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Ultragenyx|Price to Sales Beam Therapeutics Inc BEAM|Price-to-Revenue Ratio Sarepta Therapeutics Inc (SRPT)|Price-to-Revenue Coefficient Twist Bioscience Corp|P/S Multiple TXG (10x Genomics, Inc.)|NTLA - Market Cap to Revenue|Stoke Therapeutics, Inc. - P/S Multiple|Price-to-Revenue Coefficient BioLife Solutions Inc BLFS|WVE: P/S Multiple|Price to Sales Maze Therapeutics Corp (MAZE)|Price-to-Revenue Ratio Sionna Therapeutics Inc|Market Cap to Revenue Ratio PRME (primemedicine.com)|P/S Multiple TSHA|Market Cap to Revenue uniQure NV QURE|P/S Multiple MGTX (MeiraGTx PLC)|REGENXBIO Corp (RGNX) - Price to Sales|SLDB - Price-to-Revenue Ratio|Price-to-Revenue Coefficient ocugen.com OCGN|PACB: P/S Multiple|Market Cap to Revenue Ratio BNTC|Market Cap to Revenue DSGN|RCKT (Rocket Corp) - Market Cap to Sales Volume|P/S Multiple FDMT|Price-to-Revenue Coefficient lexeotx.com|Price-to-Revenue Ratio Korro Bio KRRO|Editas Medicine Inc - Price-to-Revenue Ratio|Silence Therapeutics Inc. - P/S Multiple|PRQR (ProQR Therapeutics N.V.) - Market Cap to Revenue Ratio|codexis.com (CDXS) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio SGMO|NAUT (Nautilus Biotechnology, Inc.) - P/S Multiple|P/S Multiple Metagenomi Inc.|Price-to-Revenue Ratio Generation Bio Co. (GBIO)|BOLD: Price-to-Sales Ratio|Price-to-Revenue Ratio Exicure XCUR|Market Capitalization-to-Revenue Ratio IMNN|RXi Pharmaceuticals - P/S Multiple|Price to Sales Mustang Bio, Inc.|RNAZ: P/S Multiple|Market Cap to Revenue Bionano Genomics|APDN (Applied DNA Sciences) - P/S Multiple|bluebirdbio.com (BLUE) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio ImmunoPrecise Antibodies (IPA)|Price-to-Revenue Coefficient Omega Therapeutics Inc|P/S Multiple OMIC (Singular Genomics Systems Inc)|Price-to-Revenue Coefficient Regulus (RGLS)|SYRS - Price-to-Revenue Ratio|Price to Sales telesisbio.com|TRACON Pharmaceuticals, Inc. (TCON) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio UBX